SARS-CoV-IN-5
SARS-CoV-IN-5 (compound 49) is a highly selective, nonpeptidic and noncovalent 3CLpro inhibitor with IC50s of 38 nM, 21.1 nM and 86 nM for 3CLpro of SARS-CoV-1, SARS-CoV-2, Bat coronavirus WIV1, respectively. SARS-CoV-IN-5 inhibits the replication of the SARS-CoV-2 delta variant with an EC50 of 0.272 μM. SARS-CoV-IN-5 significantly reduces the lung viral copies in a K18-hACE2 transgenic mouse model. SARS-CoV-IN-5 has good target-specific and potential broad-spectrum anticoronavirus activities against SARS-CoV-1, WIV1, MERS, HCoV-OC43, HCoV-229E, and HKU9.
For research use only. We do not sell to patients.
- Formula: C28H30BrFN6O5
- Molecular Weight:629.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero C1008 | CC50 |
>200 μM
Compound: 49
|
Cytotoxicity against African green monkey Vero E6 cells incubated for 24 hrs by CCK8 assay
Cytotoxicity against African green monkey Vero E6 cells incubated for 24 hrs by CCK8 assay
|
[PMID: 39072488] |
In Vitro
SARS-CoV-2-IN-96 exhibits moderate inhibitory effects against the 3CLpro of MERS-CoV (IC50=1.68 μM), HCoV-OC43 (IC50=0.94μM), HCoV-229E (IC50=2.56 μM), and Bat coronavirus HKU9 (IC50=0.402 μM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
Molecular Weight 629.48
-
Formula C28H30BrFN6O5
-
SMILES
O=C(N1CCN(C)CC1)C2=CC(Br)=CC([N+]([O-])=O)=C2N[C@H]3[C@H](CCCC3)NC(C(C4=CC=CC(F)=C4N5)=CC5=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)